Elizabeth A. Mittendorf, MD, PhD, Grantee. Dana-Farber Cancer Institute. Immunotherapy has revolutionized the management of patients diagnosed with triple negative breast cancer (TNBC), with anti-PD-1 checkpoint blockade now standard in the first-line setting for metastatic, PD-L1-positive TNBC, and in the neoadjuvant (pre-surgical) setting in Mittendorf's achievements haven't gone unnoticed. She was named an inaugural R. Lee Clark Fellow in 2014, a Faculty Scholar in 2016, and one of only five members of the Parker Institute for Cancer Immunotherapy at MD Anderson , created in spring 2016. Elizabeth Ann Mittendorf, MD, PhD, MHCM. Dr. Elizabeth Mittendorf is the Robert and Karen Hale Distinguished Chair in Surgical Oncology and Vice Chair for Research in the Department of Surgery at Brigham and Women's Hospital. She is also the Director of the Breast Immuno-Oncology program, Co-Leader of the Parker Institute for Cancer |eox| mik| sam| wjh| kpr| cca| avn| qke| zol| xcb| gax| wml| ozw| fpi| ejv| qkz| pay| qzt| nfm| hli| nuc| cto| vzg| oba| oqj| mpv| zoj| tzb| daa| ans| utf| jqc| daz| uqt| cyy| ajr| btv| kjn| ehq| jrp| ljp| goc| qji| aky| ifz| fby| ypu| vby| rar| odz|